Report Reveals 70% of Medtechs Use Manual Processes for Managing Content and Claims
Veeva Systems released findings from their 2024 MedTech Commercial Benchmark survey, revealing that nearly 70% of medtech organizations still use manual processes for managing commercial content and claims. Only 15% of organizations have streamlined processes with centralized data repositories. The survey of over 130 commercial medtech leaders highlighted that 80% are pursuing content personalization strategies, while 40% lack Digital Asset Management systems. 60% of companies using manual processes experience approval times exceeding four weeks, with assets requiring 3-5 review rounds. Additionally, 45% of organizations view content creation as AI's most significant potential contribution.
Veeva Systems ha pubblicato i risultati del loro sondaggio 2024 MedTech Commercial Benchmark, rivelando che quasi il 70% delle organizzazioni medtech utilizza ancora processi manuali per gestire contenuti commerciali e richieste. Solo il 15% delle organizzazioni ha riportato processi semplificati con repository di dati centralizzati. Il sondaggio, condotto su oltre 130 leader commerciali del settore medtech, ha messo in evidenza che l'80% delle aziende sta perseguendo strategie di personalizzazione dei contenuti, mentre il 40% non dispone di sistemi di gestione degli asset digitali. Inoltre, il 60% delle aziende che utilizzano processi manuali sperimenta tempi di approvazione superiori a quattro settimane, con risorse che richiedono 3-5 cicli di revisione. Infine, il 45% delle organizzazioni considera la creazione di contenuti come il contributo più significativo dell'IA.
Veeva Systems publicó los hallazgos de su encuesta 2024 MedTech Commercial Benchmark, revelando que casi el 70% de las organizaciones de medtech aún utilizan procesos manuales para gestionar contenido comercial y reclamaciones. Solo el 15% de las organizaciones ha optimizado los procesos con repositorios de datos centralizados. La encuesta, realizada a más de 130 líderes comerciales de medtech, destacó que el 80% está persiguiendo estrategias de personalización de contenido, mientras que el 40% carece de sistemas de Gestión de Activos Digitales. El 60% de las empresas que usan procesos manuales experimentan tiempos de aprobación superiores a cuatro semanas, con activos que requieren de 3 a 5 rondas de revisión. Además, el 45% de las organizaciones ven la creación de contenido como la contribución más significativa de la IA.
비바 시스템즈는 2024년 MedTech 상업 벤치마크 설문조사의 결과를 발표하며, 거의 70%의 medtech 조직이 여전히 상업 콘텐츠 및 청구 관리를 위해 수동 프로세스를 사용하고 있다고 밝혔습니다. 오직 15%의 조직만이 중앙 집중식 데이터 저장소로 프로세스를 간소화했습니다. 130명 이상의 상업 medtech 리더를 대상으로 한 설문조사에서 80%가 콘텐츠 개인화 전략을 추구하고 있는 반면, 40%는 디지털 자산 관리 시스템이 부족하다고 합니다. 수동 프로세스를 사용하는 기업의 60%는 승인 시간이 4주를 초과하는 경험을 하며, 자산은 3-5회의 검토 라운드를 요구합니다. 또한, 45%의 조직은 콘텐츠 생성이 AI의 가장 중요한 잠재적 기여로 보고 있습니다.
Veeva Systems a publié les résultats de son enquête 2024 MedTech Commercial Benchmark, révélant que près de 70% des organisations medtech utilisent encore des processus manuels pour gérer le contenu commercial et les demandes. Seules 15% des organisations ont des processus rationalisés avec des référentiels de données centralisés. L'enquête réalisée auprès de plus de 130 leaders commerciaux du secteur medtech a mis en avant que 80% poursuivent des stratégies de personnalisation des contenus, tandis que 40% manquent de systèmes de Gestion des Actifs Numériques. 60% des entreprises utilisant des processus manuels connaissent des délais d'approbation dépassant quatre semaines, avec des ressources nécessitant de 3 à 5 rounds de révision. De plus, 45% des organisations considèrent que la création de contenu est la contribution la plus significative de l'IA.
Veeva Systems hat die Ergebnisse ihrer Umfrage 2024 MedTech Commercial Benchmark veröffentlicht, die zeigt, dass fast 70% der Medtech-Organisationen weiterhin manuelle Prozesse zur Verwaltung von kommerziellen Inhalten und Ansprüchen nutzen. Nur 15% der Organisationen haben ihre Prozesse mit zentralen Datenrepositories optimiert. Die Umfrage unter mehr als 130 kommerziellen Medtech-Führungskräften hob hervor, dass 80% personalisierende Inhaltsstrategien verfolgen, während 40% keine Systeme zur digitalen Asset-Verwaltung haben. 60% der Unternehmen, die manuelle Prozesse nutzen, erleben Genehmigungszeiten von mehr als vier Wochen, wobei Assets 3-5 Überprüfungsrunden erfordern. Darüber hinaus sehen 45% der Organisationen die Inhaltserstellung als den bedeutendsten Beitrag der KI.
- 80% of medtech companies are pursuing content personalization strategies
- 45% recognize AI's potential in content creation
- 70% still rely on manual processes for content and claims management
- 60% experience content approval delays exceeding 4 weeks
- Only 15% have streamlined processes with centralized data repositories
- 40% lack Digital Asset Management (DAM) systems
- Marketing assets require 3-5 rounds of reviews, causing launch delays
Insights
The survey reveals significant operational inefficiencies in the medtech sector that directly impact market competitiveness. With
The low
The industry's struggle with digital transformation presents a clear opportunity for Veeva's PromoMats platform. The high percentage of manual processes indicates significant technical debt in the sector, while the growing demand for AI-driven content creation (
This technological gap, particularly in automated compliance and content personalization at scale, suggests strong potential for Veeva to expand its market share by offering solutions that address these specific pain points. The data indicates a market ripe for digital transformation, benefiting established players like Veeva with proven solutions.
Reducing content approvals from more than four weeks and automating claims are key opportunities to drive speed to market
Despite the importance of connecting claims, evidence, and promotional materials, only
The benchmark survey of over 130 commercial medtech leaders found that:
- Content personalization is a growing focus. More than
80% are pursuing strategies to tailor and specify messaging. Achieving compliant personalization at scale without the right systems remains a challenge amid strict regulatory requirements. - Digital asset management (DAM) not yet in place for true omnichannel. Nearly
40% of organizations report not having a DAM system in place, limiting the management of personalizing content. Among those with a DAM, only31% report having it accessible across marketing. - Prolonged approval times result in missed opportunities.
60% of medtech companies using manual processes or homegrown solutions experience approvals taking more than four weeks. Marketing assets undergo an average of three to five rounds of reviews which can delay campaign launches, affecting product awareness and sales momentum. - AI and automation of content continues to influence medtech.
45% of medtech organizations feel the most significant area AI can contribute is content creation.
"As the demand grows for more personalized promotional materials, medtech companies face scale and compliance challenges to adhere to regulatory standards and accurately reflect product efficacy and safety," said Jeff Gorski, senior director of commercial content strategy, Veeva MedTech. "This report shows that nearly every medtech organization has an opportunity to improve content and claims management processes for greater speed to market, compliance, and efficiency."
The 2024 Veeva MedTech Commercial Benchmark survey examines the current processes, challenges, and future opportunities for improvement in managing promotional content and claims.
Additional Information
For more on Veeva Vault PromoMats for MedTech, visit: veeva.com/medtech/PromoMats
Connect with Veeva on LinkedIn: https://www.linkedin.com/showcase/veeva-medtech/
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Alison Borris
Veeva Systems
925-226-8821
alison.borris@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/report-reveals-70-of-medtechs-use-manual-processes-for-managing-content-and-claims-302312460.html
SOURCE Veeva Systems
FAQ
What percentage of medtech companies use manual processes for content management according to Veeva's 2024 survey?
How long do content approvals take for medtech companies using manual processes (VEEV)?
What percentage of medtech organizations have centralized data repositories for claims management (VEEV)?
How many medtech organizations view AI as significant for content creation according to Veeva's 2024 survey?
